Viewing Study NCT02206568


Ignite Creation Date: 2025-12-24 @ 5:28 PM
Ignite Modification Date: 2026-02-28 @ 5:57 PM
Study NCT ID: NCT02206568
Status: WITHDRAWN
Last Update Posted: 2020-07-15
First Post: 2014-07-30
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus
Sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Type 1 Diabetes Mellitus View
Keywords:

Keywords

Keyword Brief Keyword Text View
None diabetes mellitus View
None phase 1 View
None insulin lispro View
None male subjects View